Supplementary material

An K, Guo P, Qiu S, et al. Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drug-eluting stent implantation: a Bayesian network meta-analysis. Pol Arch Intern Med. 2021; 131: 781-789. doi:10.20452/pamw.16032

Supplementary material

Table of Contents

Table S1. Search strategy

ID	Searches	Result
1	Search eluting stent[MeSH Terms]	11758
2	Search coronary stent*[Title/Abstract]	7334
3	Search eluting stent*[Title/Abstract]	13570
4	Search coronary angioplast*[Title/Abstract]	13103
5	Search ((coronary [Title/Abstract] AND dilatation*[Title/Abstract]))	5105
6	Search Percutaneous Coronary Intervention[MeSH Terms]	54425
7	Search (percutaneous coronary[Title/Abstract]) AND (interven*[Title/Abstract] OR revascular*[Title/Abstract])	36683
8	Search PCI[Title/Abstract]	26846
9	Search coronary atherectom*[Title/Abstract]	788
10	Search (1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9)	90258
11	Search Platelet Aggregation Inhibitors[MeSH Terms]	36675
12	Search thienopyridine derivative[Text Word]	62
13	Search (antiplatelet*[Title/Abstract] OR anti-platelet*[Title/Abstract] OR antithrombocytic[Title/Abstract] OR anti-thrombocytic[Title/Abstract])	32584
14	Search (cyclooxygenase inhibitor*[Title/Abstract] OR thienopyridine*[Title/Abstract])	6246
15	Search (thromboxane A2[Title/Abstract]) AND (inhib*[Title/Abstract] OR antag*[Title/Abstract])	4861
16	Search aspirin[MeSH Terms]	45148
17	Search (clopidogrel[Title/Abstract] OR ticagrelor[Title/Abstract] OR prasugrel[Title/Abstract])	14176
18	Search dual antiplatelet[Text Word]	5126
19	Search (11 or 12 or 13 or 14 or 15 or 16 or 17 or 18)	99356
20	Search (10 and 19)	12377
21	Search (animals[MeSH Terms]) NOT humans[MeSH Terms]	4743556
22	Search Animals, Laboratory[MeSH Terms]	881731
23	Search Animal Experimentation[MeSH Terms]	9505
24	Search Models, Animal[MeSH Terms]	574454
25	Search rodentia[MeSH Terms]	3247400
26	Search (rat[Title] OR rats[Title] OR mouse[Title] OR mice[Title])	1341666
27	Search (21 or 22 or 23 or 24 or 25 or 26)	5675371
28	Search (20 not 27)	12198
29	Search ((randomized controlled trial[Publication Type]) OR randomized controlled trial[MeSH Terms]) OR Randomized Controlled Trials as Topic[MeSH Terms]	648583
30	Search controlled clinical trial[Publication Type]	605072
31	Search (randomized[Title/Abstract]) OR randomised[Title/Abstract]	639627
32	Search placebo[Title/Abstract]	217404
33	Search randomly[Title/Abstract]	343015

34	Search trial[Title]	226307
35	Search (29 or 30 or 31 or 32 or 33 or 34)	1282639
36	Search (28 and 35)	3704
37	Search diabetes mellitus[MeSH Terms]	436643
38	Search diabet*[Title/Abstract]	645982
39	Search (37 or 38)	705731
40	Search (36 and 39) Filters: Publication date to 2020/10/11	361

Table S2. Definition of primary endpoint

No.	Trial	Definition
1	REAL/ZEST-LATE	MI or death from cardiac causes
2	RESET	Death from cardiovascular cause, MI, stent thrombosis, TVR or bleeding
3	EXCELLENT	A composite of death, MI, stroke, stent thrombosis, or TIMI major bleeding
4	OPTIMIZE	A composite of all-cause death, MI stroke or major bleeding
5	ARCTIC-Interruption	The composite of death, MI, stent thrombosis, stroke or urgent revascularization
6	DES LATE	A composite of death resulting from cardiac causes, myocardial infarction, or stroke
7	ISAR-SAFE	Composite of death, myocardial infarction, stent thrombosis, stroke, and thrombolysis in MI major bleeding
8	ITALIC	A composite of death, MI, urgent TVR, stroke, and major bleeding
9	SECURITY	A composite of cardiac death, MI, stroke, definite or probable stent thrombosis, or bleeding BARC 2,3 or 5
10	I-LOVE-IT 2	A composite of all-cause death, all MI, stroke, or major bleeding
11	IVUS-XPL	The composite of cardiac death, MI, stroke, or TIMI major bleeding
12	GLOBAL LEADERS	A composite of all-cause death or non-fatal new Q-wave MI
13	STOPDAPT-2	A composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding
14	SMART-DATE	A composite of all-cause death, MI or stroke
15	REDUCE	A composite of all-cause mortality, MI, stent thrombosis, stroke, TVR and bleeding

BARC: Bleeding Academic Research Consortium; MI: myocardial infarction; TIMI: Thrombolysis in Myocardial Infarction; TVR: target vessel revascularization

Table S3. Definition of major bleeding

No.	Trial	Definition
1	REAL/ZEST-LATE	TIMI Major
2	EXCELLENT	TIMI Major
3	OPTIMIZE	Incorporated modified major REPLACE-2 and severe or life-threatening GUSTO criteria
4	DAPT	BARC 3 or 5
5	OPTIDUAL	TIMI major
6	SECURITY	BARC 3 or 5
7	I-LOVE-IT 2	BARC 3 or 5
8	GLOBAL LEADERS	BARC 3 or 5
9	TWILIGHT	BARC 3 or 5

BARC: Bleeding Academic Research Consortium; GUSTO: Global Utilization of Streptokinase and TPA for Occluded arteries; REPLACE: Randomized Evaluation in PCI Linking Angiomax to reduced Clinical Events; TIMI: Thrombolysis in Myocardial Infarctio

Table S4. Inclusion and exclusion criteria of included studies

Trial	Inclusion criteria	Exclusion criteria
REAL/ZEST-LATE	DES implant >12-month before enrollment, no history of MACE or major bleeding since implant, receiving DAPT at the time of enrollment	Contraindications to antiplatelet drugs, history of vascular disease requiring long-term use of clopidogrel or other indication for clopidogrel life expectancy <1 year or noncompliance with the study protocol or participating in trial
RESET	20-85 years old, ≥50% DS, RVD ≥2.5-4.0 mm, elective PCI, stable or unstable angina, or acute MI	Cerebral or peripheral atherosclerotic arterial disease, thromboembolic disease or stent thrombosis history, <40% LVEF, restenotic lesion, CTO, LM disease requiring intervention, cardiogenic shock, <48-h STEMI
EXCELLENT	≥1 de novo lesion, native coronary vessel, RVD ≥2.25-4.25 mm, >50% DS, stable angina, unstable angina, recent MI, silent ischemia, positive functional study, or reversible changes on EKG consistent with ischemia	<72-h MI; <25% LVEF or cardiogenic shock, any stent implantation in target vessel before enrolment, major bleeding <3-month, major surgery <2-month, elective surgery planned <12-month; >50% DS on LM, CTO, true bifurcation lesions requiring a planned two stent strategy
OPTIMIZE	Stable angina or silent ischemia or low risk ACS as defined by unstable angina or recent (but not acute) MI (<30 days)	Elevated biomarker levels at time of index procedure and ≥1 lesion with stenosis >50% (MVD allowed) located in a native vessel >2.5 mm diameter with indication for PCI with stent implantation, STEMI presenting for primary or rescue PCI, PCI with BMS in nontarget lesions <6 months before index procedure, previous treatment with any DES, scheduled elective surgery within 12 months after index procedure, contraindication, intolerance, or known hypersensitivity to aspirin, clopidogrel, or both, lesion in a saphenous vein graft, or in-stent restenosis of DES
ARCTIC-Interruption	≥18 years and eligible for PCI with planned use of ≥1 DES, without use of a GPIIb/IIIa inhibitor at randomization, able to understand and comply with study procedures and protocol	Anticoagulation with vitamin K antagonist, contraindication to aspirin or clopidogrel, GPIIb/IIIa inhibitors, or increased dose regimen of aspirin/clopidogrel, ongoing or recent bleeding or major surgery <3 weeks, severe liver insufficiency, platelet count <80 000/μ, GPIIb/IIIa inhibitor before randomization; primary PCI for STEMI; history of major bleeding with

		contraindication to antiplatelet therapy, scheduled surgery <12-month, high risk feature of poor compliance to DAPT
DAPT	>18 years old, undergoing PCI with stent deployment	Index procedure stent placement with stent diameter <2.25 mm or >4.0 mm, pregnancy, planned surgery mandating discontinuation of antiplatelet therapy within 30 months after enrollment, life expectancy of <3-year, enrollment in another device or drug study whose protocol specifically rules out concurrent enrollment or involves blinded placement of a DES or BMS other than those included as DAPT study devices, warfarin or similar anticoagulant therapy, hypersensitivity or allergies to one of the drugs or DES components, patient treated with both DES and BMS during index procedure
DES LATE	<12-month DES, no MACE (MI, stroke, repeat PCI) or major bleeding since PCI, DAPT	DAPT contraindications due to bleeding diathesis or major bleeding history, long term DAPT indication due to concomitant vascular disease or recent ACS
ISAR-SAFE	Patients on clopidogrel at 6 (−1/+2) months after PCI with DES	Clinical symptoms or signs of ischemia or angiographic lesions requiring revascularization, active bleeding, bleeding diathesis, history of intracranial bleeding, STEMI and NSTEMI during last 6 months after DES, previous stent thrombosis, DES in left main coronary artery at index intervention, oral anticoagulation, planned major surgery within next 6 months with need to discontinue antiplatelet therapy
ITALIC	≥18-year old eligible for PCI, with ≥1 Xience DES in all clinical situations excluding primary PCI for acute MI and treatment of left main disease	Non-responders to aspirin, previous DES implantation within 1-year, known platelet level <100 000/μL or known hemorrhagic diathesis, oral anticoagulation therapy or abciximab treatment during hospital stay, contraindications to aspirin or clopidogrel (prasugrel or ticagrelor), major surgery within preceding 6 weeks, evidence of active gastrointestinal or urogenital bleeding, severe liver failure, any surgery scheduled within 1 year
OPTIDUAL	Stable angina, silent ischemia, or ACS with ≥1 lesion with stenosis >50% located in a native vessel ≥2.25 mm in diameter and who were	Need for oral anticoagulation, DES implantation in an unprotected left main coronary artery, malignancies or other coexisting conditions associated with a life expectancy of < 2-year after enrolment, or severe concomitant disease with

	implanted with ≥1 DES of any type	<2 years' life expectancy
SECURITY	>18 years old, stable angina, as defined by CCS or unstable angina, as defined by Braunwald classification, or patients with documented silent ischemia, treated with≥1 second generation DES implanted in the target lesion past 24-h; presence of ≥1 de novo stenosis ≥70% in a native coronary artery, no other DES implanted before target procedure and no BMS implanted in 3 months before target procedure	STEMI in 48-h before the procedure, NSTEMI in previous 6 months, LVEF <30%, known hypersensitivity to aspirin, thienopyridines, heparin, cobalt, chromium, nickel, molybdenum, or contrast media, target lesion in saphenous vein graft, in-stent restenosis, unprotected LM, history of significant thrombocytopenia with aspirin or thienopyridines, patients with chronic kidney disease (creatinine >2 mg/dL), women during pregnancy or lactation, active bleeding or significant risk of bleeding, uncontrolled hypertension, life expectancy <24 months and any medical condition that could preclude follow-up as defined in protocol
I-LOVE-IT 2	Stable CAD or ACS, Age ≥18 years, at least 1 coronary lesion with stenosis >70%, patients with MVD must undergo complete revascularization within 30 days using the same study stents	Intolerance to a study drug, antiplatelet therapy, metal alloys, or contrast media, life expectancy <1 year, re-stenosed lesions, stent implantation within 1 year, LVEF <40%, severe renal or hepatic dysfunction, hemodynamic instability, planned surgery within 6 months, childbearing potential within 1-year
IVUS-XPL	Age >20-year, typical chest pain or evidence of myocardial ischemia, stent length >28 mm based on angiographic estimation, >50% coronary artery stenosis	Acute MI within 48-h, contraindication to antiplatelet, history of stroke, peripheral artery occlusive disease, thromboembolic disease, stent thrombosis, age > 80 years, severe hepatic dysfunction, renal dysfunction, cardiogenic shock, LVEF< 40%, left main disease requiring PCI, bifurcation lesion with 2-stent technique, CTO, DES within 6-month, in-stent restenosis lesion
GLOBAL LEADERS	Age ≥18 years, clinical indication for PCI, presence of one or more coronary artery stenosis of ≥50% in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation in a vessel with a reference	Intolerance to aspirin, P2Y12 inhibitors, bivalirudin, stainless steel or biolimus, known intake of a strong cytochrome P3A4 inhibitor as co-administration may lead to a substantial increase in exposure to ticagrelor, use of fibrinolytic therapy within 24 h of PCI, planned CABG as a staged procedure (hybrid) within 12 months of the index procedure, planned surgery within 12 months of PCI unless DAPT is maintained throughout the peri-surgical period, need for

	vessel diameter of at least 2.25 mm	oral anti-coagulation therapy, PCI for a priori known stent thrombosis, overt major bleeding, history of intracranial hemorrhage, stroke from ischemic or unknown cause within last 30 days
STOPDAPT-2	Patients who have undergone PCI with the everolimus-eluting cobalt-chromium stent (CoCr-EES, XienceTM) and have not experienced major complications (death, MI, stroke, or major bleeding) during hospital stay for treatment	DES other than Xience implanted in PCI performed at the time of enrollment, need for oral anticoagulation or antiplatelet therapy other than aspirin and P2Y12 inhibitors, history of intracranial bleeding, and known intolerance to clopidogrel
SMART-CHOICE	Age ≥ 20 years, ≥1 coronary artery stenoses of 50% or greater in a native coronary artery with visually estimated diameter of ≥ 2.25 mm and ≤4.25 mm or smaller amenable to stent implantation, and underwent PCI	Hypersensitivity or contraindication to aspirin, clopidogrel, prasugrel, ticagrelor, everolimus, or sirolimus, hemodynamic instability or cardiogenic shock, active pathologic bleeding, DES implantation within 12 months before the index procedure, women of childbearing potential, noncardiac comorbid conditions with a life expectancy <2 years, or conditions that may result in protocol nonadherence
REDUCE	Age >18, successful COMBO stent placement, no clinical adverse event during index hospitalization, ACS	Cardiogenic shock, contraindication to DAPT, recent major bleeding, planned cardiac surgery or intervention of another lesion after index hospital discharge, revascularization with other than COMBO stent, need for permanent DAPT, recent DES within 9 months, organ transplant, limited life expectancy
TWILIGHT	Clinical criteria (at least 1): Age >65, female sex, troponin positive ACS, Established vascular disease, DM, CKD AND Angiographic criteria (at least 1): multivessel CAD, stent length > 30 mm, thrombotic target lesion, bifurcation lesion, left main > 50% or proximal LAD > 70% lesion, calcified target lesion requiring atherectomy	Under 18, contraindication to aspirin or ticagrelor, planned surgery within 90 days, planned coronary revascularization within 90 days, need for chronic oral anticoagulation, prior stroke, dialysis-dependent renal failure, active bleeding or extreme risk for major bleeding, salvage PCI for cardiogenic shock or STEMI presentation, liver cirrhosis, life expectancy <1-year, unable or unwilling to provide informed consent, women of childbearing potential, fibrinolytic therapy within 24 h of PCI, concomitant therapy with a strong cytochrome P450 3A inhibitor or inducer, platelet count <100,000, requiring ongoing treatment with aspirin > 325 mg daily

ACS= Acute coronary syndrome; ARCTIC =Assessment by a double Randomization of a Conventional antiplatelet strategy versus a monitoringguided strategy for drug-eluting stent implantation and, of Treatment Interruption versus Continuation 1 year after stenting; BMS=Bare-metal stent; CAD= Coronary artery disease; CCS=Canadian Cardiovascular Society; CKD= chronic kidney disease; CTO=Chronic total occlusion; DAPT = Dual Antiplatelet Therapy; DES=Drug eluting stent; DES LATE=the Optimal Duration of Clopidogrel Therapy With DES to Reduce Late Coronary Arterial Thrombotic Event Trial; DM= Diabetes mellitus; DS= Percent diameter stenosis; ECG=Electrocardiogram; EXCELLENT= The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting Trial; GLOBAL LEADERS=A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation;TVR=Target Vessel Revascularization; GP=Glycoprotein; I-LOVE-IT 2=Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization Trial; ISAR-SAFE= Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6-month Dual Antiplatelet Therapy After Drug-Eluting Stenting Trial; ITALIC= Is There A LIfe for DES after Discontinuation of Clopidogrel Trial; IVUS-XPL=Impact of Intravascular Ultrasound Guidance on Outcomes of XIENCE PRIME Stents in Long Lesions Study; LAD= Left anterior descending; LM= left main trunk; LVEF=Left ventricle; MACE=Major adverse cardiac events; MI=Myocardial infarction; MVD=Multivessel disease; NSTEMI=non-ST segment elevation myocardial infarction; OPTIDUAL=The OPTImal DUAL antiplatelet therapy Trial; OPTIMIZE= Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in RealWorld Clinical Practice; PCI=percutaneous coronary intervention; REAL-ZEST LATE= Correlation of Clopidogrel Therapy Discontinuation in Real World Patients Treated with Drug-Eluting Stent Implantation-Evaluation of the Long-Term Safety after Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary Lesions Late Coronary Arterial Thrombotic Events; REDUCE=Randomized evaluation of short-term dual antiplatelet8 therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent; RESET=REal Safety and Efficacy of 3-month dual antiplatelet therapy following Endeavor Zotarolimus-eluting stent implantation; RVD=reference vessel diameter; SECURITY= Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy; SMART-CHOICE=Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents; STEMI=ST segment elevation myocardial infarction; STOPDAPT-2=Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting CobaltChromium Stent; TIA=transient ischemic attack; TWILIGHT = Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention

Table S5. Heterogeneity estimates on different outcomes

Primary endpoint		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
RESET	1.3 (0.59, 3.1)	
OPTIMIZE	1.1 (0.68, 1.8)	
GLOBAL LEADERS	1.3 (0.99, 1.7)	
STOPDAPT-2	1.4 (0.78, 2.7)	
SMART-CHOICE	0.89 (0.48, 1.6)	
REDUCE	0.97 (0.51, 1.8)	
Pooled (pair-wise)	1.2 (0.80, 1.7)	0.0%
Indirect (back-calculated)	NA	
Pooled (network)	1.2 (0.83, 1.6)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	0.29 (0.13, 0.68)	
ISAR-SAFE	1.4 (0.57, 3.4)	
SECURITY	1.5 (0.71, 3.3)	
I-LOVE-IT 2	0.93 (0.48, 1.8)	
IVUS-XPL	1.6 (0.50, 5.3)	
Pooled (pair-wise)	0.93 (0.58, 1.5)	62.1%
Indirect (back-calculated)	0.85 (0.37, 1.9)	
Pooled (network)	0.91 (0.60, 1.4)	53.0%
Extended-term DAPT vs midterm DAPT		
ITALIC	1.5 (0.70, 3.0)	
Pooled (pair-wise)	1.5 (0.53, 4.1)	
Indirect (back-calculated)	1.7 (0.83, 3.5)	
Pooled (network)	1.6 (0.93, 3.0)	0.0%
Extended-term DAPT vs standard-term DAPT		
REAL/ZEST-LATE	18 (1.4, 230)	
ARCTIC-Interruption	1.2 (0.51, 3.1)	
DES LATE	1.6 (0.92, 2.8)	
Pooled (pair-wise)	1.9 (1.1, 3.9)	52.4%
Indirect (back-calculated)	1.6 (0.64, 3.9)	
Pooled (network)	1.8 (1.1, 3.1)	24.8%
All-cause mortality		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
OPTIMIZE	0.91 (0.48, 1.7)	
Pooled (pair-wise)	0.91 (0.17, 4.9)	
Indirect (back-calculated)	1.1 (0.30, 3.8)	
Pooled (network)	1.0 (0.35, 2.7)	0.0%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	1.5 (0.81, 2.8)	

Pooled (pair-wise)	0.91 (0.17, 4.9)	
Indirect (back-calculated)	1.1 (0.30, 3.8)	
Pooled (network)	1.0 (0.35, 2.7)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	1.6(0.22, 12)	
SECURITY	1.5 (0.20, 11)	
I-LOVE-IT 2	0.17 (0.011, 2.5)	
Pooled (pair-wise)	0.83 (0.20, 3.3)	5.4%
Indirect (back-calculated)	1.0 (0.24,4.4)	
Pooled (network)	0.92 (0.33, 2.5)	0.0%
Extended-term DAPT vs midterm DAPT		
ITALIC	1.4 (0.52, 3.9)	
Pooled (pair-wise)	1.4 (0.23,8.8)	
Indirect (back-calculated)	1.2 (0.35, 4.4)	
Pooled (network)	1.3 (0.46, 3.7)	0.0%
Extended-term DAPT vs standard-term DAPT		
REAL/ZEST-LATE	4.6 (1.2, 18)	
DAPT	1.3 (0.81, 2)	
OPTIDUAL	0.61 (0.24, 1.5)	
Pooled (pair-wise)	1.3 (0.51,3.9)	66.0%
Indirect (back-calculated)	1.4 (0.54, 3.8)	
Pooled (network)	1.4 (0.72, 2.9)	50.7%
Cardiac mortality		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
RESET	0.96 (0.030, 30)	
OPTIMIZE	1.0 (0.48, 2.1)	
Pooled (pair-wise)	1.0 (0.33, 3.1)	0.0%
Indirect (back-calculated)	1.4 (0.44, 4.8)	
Pooled (network)	1.2 (0.54, 2.8)	0.0%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	1.3 (0.65, 2.6)	
Pooled (pair-wise)	1.3 (0.39, 4.3)	
Indirect (back-calculated)	0.91 (0.28, 2.9)	
Pooled (network)	1.1(0.45, 2.4)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	0.91 (0.029, 28)	
SECURITY	1.6 (0.35, 7.7)	
I-LOVE-IT 2	0.23 (0.015, 3.7)	
Pooled (pair-wise)	0.91 (0.25, 3.2)	0.0%
Indirect (back-calculated)	0.75 (0.11, 5.0)	
Pooled (network)	0.86 (0.30, 2.4)	0.0%
Extended-term DAPT vs midterm DAPT		

ITALIC	0.58 (0.080, 4.2)	
Pooled (pair-wise)	0.59 (0.059, 5)	
Indirect (back-calculated)	0.85 (0.22, 3.4)	
Pooled (network)	0.77 (0.23, 2.4)	0.0%
Extended-term DAPT vs standard-term DAPT		
DAPT	1.1 (0.64, 2)	
OPTIDUAL	0.37 (0.11, 1.3)	
Pooled (pair-wise)	0.82 (0.30, 1.8)	63.3%
Indirect (back-calculated)	1.0 (0.36, 3)	
Pooled (network)	0.90 (0.43,1.7)	22.0%
Myocardial infarction		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
RESET	3.7e+04 (0.0024, 5.5e+11)	
OPTIMIZE	1.1 (0.54, 2.1)	
Pooled (pair-wise)	1.3 (0.35, 6.2)	40.5%
Indirect (back-calculated)	1.6 (0.53, 5.1)	
Pooled (network)	1.5 (0.63,3.7)	13.9%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	1.3 (0.88, 2.0)	
Pooled (pair-wise)	1.4 (0.32, 5.7)	
Indirect (back-calculated)	1.1 (0.37, 3.3)	
Pooled (network)	1.2(0.52, 3)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	0.21 (0.053, 0.81)	
SECURITY	1.2 (0.62, 2.5)	
I-LOVE-IT 2	1.3 (0.62, 2.6)	
Pooled (pair-wise)	0.86 (0.31, 2)	68.7%
Indirect (back-calculated)	0.98 (0.34, 2.9)	
Pooled (network)	0.91 (0.43, 1.7)	51.2%
Extended-term DAPT vs midterm DAPT		
ITALIC	0.96 (0.22, 4.2)	
Pooled (pair-wise)	0.96 (0.13, 7.1)	
Indirect (back-calculated)	0.69 (0.26, 1.9)	
Pooled (network)	0.74 (0.29, 1.7)	0.0%
Extended-term DAPT vs standard-term DAPT		
REAL/ZEST-LATE	0.60 (0.13, 2.8)	
DAPT	0.72 (0.51, 1.0)	
OPTIDUAL	0.81 (0.20, 3.3)	
Pooled (pair-wise)	0.72 (0.27, 1.9)	0.0%
Indirect (back-calculated)	0.89 (0.36, 2.2)	
Pooled (network)	0.81 (0.42, 1.6)	0.0%
Stroke		

Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
OPTIMIZE	2.6 (0.14, 49)	
Pooled (pair-wise)	2.5 (0.11, 1.1e+02)	
Indirect (back-calculated)	0.67 (0.086, 5.2)	
Pooled (network)	0.94 (0.18. 6.3)	0.0%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	0.61 (0.19, 1.9)	
Pooled (pair-wise)	0.61 (0.074, 4.8)	
Indirect (back-calculated)	1.3 (0.091, 19)	
Pooled (network)	0.82 (0.17, 4.5)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	2.6 (0.14, 50)	
SECURITY	1.7 (0.35, 7.9)	
I-LOVE-IT 2	1.7e+07 (0.0073. 3.9e+16)	
Pooled (pair-wise)	2.9 (0.68, 20)	19.8%
Indirect (back-calculated)	NA	
Pooled (network)	2.8 (0.68, 17)	17.5%
Extended-term DAPT vs standard-term DAPT		
REAL/ZEST-LATE	1.8 (0.24, 13)	
DAPT	1.0 (0.52, 2)	
OPTIDUAL	0.45 (0.067, 3.0)	
Pooled (pair-wise)	0.95 (0.27, 3.3)	0.0%
Indirect (back-calculated)	0.65 (0.061, 7)	
Pooled (network)	0.88 (0.27, 2.5)	0.0%
Target vessel revascularization		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
RESET	0.60 (0.081, 4.4)	
OPTIMIZE	0.72 (0.41, 1.3)	
Pooled (pair-wise)	0.71 (0.22, 2.2)	0.0%
Indirect (back-calculated)	NA	
Pooled (network)	0.71 (0.23, 2.0)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	0.32 (0.11, 0.93)	
SECURITY	1.6 (0.36, 7.6)	
Pooled (pair-wise)	0.59 (0.18, 2.1)	66.8%
Indirect (back-calculated)	0.77 (0.087, 6.7)	
Pooled (network)	0.63 (0.23, 1.9)	35.7%
Extended-term DAPT vs midterm DAPT		
ITALIC	0.94 (0.17, 5.4)	
Pooled (pair-wise)	0.96 (0.12, 8)	
Indirect (back-calculated)	0.66 (0.12, 3.6)	

Pooled (network)	0.76 (0.21, 3.1)	0.0%
Extended-term DAPT vs standard-term DAPT		
OPTIDUAL	1.1 (0.51, 2.5)	
Pooled (pair-wise)	1.1 (0.27, 4.9)	
Indirect (back-calculated)	1.4 (0.18, 10)	
Pooled (network)	1.2 (0.38, 4.0)	0.0%
Definite or probable stent thrombosis		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
RESET	2.4e+07 (0.00015, 3.7e+18)	
OPTIMIZE	0.72 (0.14, 3.6)	
Pooled (pair-wise)	1.6 (0.095, 48)	72.2%
Indirect (back-calculated)	1,4 (0.049, 41)	
Pooled (network)	1.5 (0.16, 15)	69.9%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	1.6 (0.53, 4.6)	
Pooled (pair-wise)	1.6 (0.056, 44)	
Indirect (back-calculated)	1.6 (0.046, 52)	
Pooled (network)	1.6(0.19, 25)	0.0%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	7.8e-13 (1.1e-29, 5.8e+04)	
SECURITY	0.51 (0.11, 2.4)	
Pooled (pair-wise)	0.17 (0.0064, 2.2)	72.2%
Indirect (back-calculated)	NA	
Pooled (network)	0.19 (0.0085, 1.9)	69.9%
Extended-term DAPT vs standard-term DAPT		
DAPT	0.46 (0.20, 1.0)	
OPTIDUAL	1.8e+08 (0.00022, 1.5e+20)	
Pooled (pair-wise)	1.2 (0.12, 31)	85.9%
Indirect (back-calculated)	0.83 (0.026, 27)	
Pooled (network)	1.0 (0.16, 12)	64.8%
Major bleeding		
Study	Odds ratio (95% CrI)	I^2
Standard-term DAPT vs short-term DAPT		
OPTIMIZE	2.2e-06 (6.8e-15, 6 .9e+02)	
GLOBAL LEADERS	0.93 (0.62, 1.4)	
Pooled (pair-wise)	0.85 (0.23, 2.3)	45.3%
Indirect (back-calculated)	1.4 (0.38 5.0)	
Pooled (network)	1.1 (0.42, 2.4)	12.3%
Extended-term DAPT vs short-term DAPT		
TWILIGHT	3.0 (1.6, 5.6)	
Pooled (pair-wise)	3 (0.85, 11)	
Indirect (back-calculated)	1.6 (0.47, 5.6)	

Pooled (network)	2.2 (0.88, 5.2)	24.6%
Standard-term DAPT vs midterm DAPT		
EXCELLENT	0.00092 (1.1e-14, 7.8e+07)	
SECURITY	1.4 (0.56, 3.6)	
I-LOVE-IT 2	0.99 (0.030, 32)	
Pooled (pair-wise)	1.3 (0.38, 4.7)	0.0%
Indirect (back-calculated)	NA	
Pooled (network)	1.3 (0.40, 4.5)	0.0%
Extended-term DAPT vs standard-term DAPT		
REAL/ZEST-LATE	2.8 (0.16, 51)	
DAPT	1.7 (1.0, 2.7)	
OPTIDUAL	1.7 (0.23, 12)	
Pooled (pair-wise)	1.7 (0.68, 4.5)	0.0%
Indirect (back-calculated)	3.2 (0.80, 12)	
Pooled (network)	2.1 (0.98, 4.6)	0.0%

Table S6. Comparisons of the fit of consistency and inconsistency models using deviance information criteria (DIC).

Model	primary endpoint	all-cause mortality	cardiac mortality	MI	stroke	TVR	stent thrombosis (definite and probable)	major bleeding
Consistency	55.90	33.21	29.76	36.51	28.31	21.83	27.60	27.16
Inconsistency	57.24	35.01	32.44	38.62	29.73	23.27	27.47	27.24

The DIC is a Bayesian model evaluation criterion that measures model fit adjusted with the complexity of the model; smaller DIC values correspond to more preferable models. (Reference: Spiegelhalter, D.J., Best, N.G., Carlin, B.P., Van der Linde, A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society Series B (Statistical Methodology) 2002; 64(4):583-639)

Table S7. Node-splitting analysis of inconsistency

Nodes	Direct effect	Indirect effect	Overall	P
Primary endpoint				
Midterm, standard-term	-0.074 (-0.54, 0.42)	-0.27 (-1.5, 0.88)	-0.10 (-0.51, 0.32)	0.73633
Midterm, extended-term	0.38 (-0.62, 1.4)	0.57 (-0.17, 1.4)	0.48 (-0.064, 1.1)	0.73786
Standard-term, extended-term	0.64 (0.047, 1.4)	0.45 (-0.73, 1.6)	0.58 (0.097, 1.1)	0.73708
All-cause mortality				
Short-term, standard-term	-0.097 (-1.6, 1.5)	0.11 (-1.7, 1.8)	-0.00027 (-1.0, 0.99)	0.813400
Short-term, extended-term	0.42 (-1.1, 2.)	0.20 (-1.5, 2.0)	0.33 (-0.66, 1.4)	0.810800
Midterm, standard-term	-0.16 (-1.5, 1.1)	0.036 (-1.8, 1.8)	-0.085 (-1.1, 0.89)	0.846475
Midterm, extended-term	0.33 (-1.3, 2.0)	0.14 (-1.4, 1.7)	0.25 (-0.80, 1.3)	0.845025
Standard-term, extended-term	0.27 (-0.59, 1.3)	0.52 (-0.95, 2.0)	0.33 (-0.33, 1.1)	0.741375
Cardiac mortality				
Short-term, standard-term	0.0084 (-1.1, 1.1)	0.47 (-0.89, 2.)	0.18 (-0.63, 1.0)	0.56440
Short-term, extended-term	0.25 (-0.91, 1.4)	-0.22 (-1.7, 1.1)	0.079 (-0.80, 0.87)	0.55055
Midterm, standard-term	-0.080 (-1.3, 1.1)	-0.41 (-2.8, 1.8)	-0.16 (-1.2, 0.89)	0.78143
Midterm, extended-term	-0.55 (-2.8, 1.5)	-0.16 (-1.7, 1.2)	-0.26 (-1.5, 0.84)	0.76340
Standard-term, extended-term	-0.20 (-1.2, 0.59)	0.083 (-1.3, 1.4)	-0.10 (-0.85, 0.53)	0.68865
Myocardial infarction				
Short-term, standard-term	0.21 (-0.97, 1.7)	0.57 (-0.99, 2.1)	0.39 (-0.47, 1.3)	0.637904
Short-term, extended-term	0.29 (-0.99, 1.6)	-0.085 (-1.5, 1.6)	0.17 (-0.67, 1.1)	0.628152
Midterm, standard-term	-0.14 (-1.1, 0.61)	0.21 (-1.8, 2.2)	-0.084 (-0.84, 0.56)	0.720776
Midterm, extended-term	-0.043 (-1.9, 1.8)	-0.39 (-1.7, 0.64)	-0.30 (-1.2, 0.53)	0.724088
Standard-term, extended-term	-0.33 (-1.2, 0.52)	0.11 (-1.2, 1.4)	-0.22 (-0.88, 0.45)	0.491008
Stroke				

Short-term, standard-term	0.87 (-2.1, 4.7)	-0.43 (-2.8, 2.)	-0.074 (-1.7, 1.9)	0.461896
Short-term, extended-term	-0.50 (-2.6, 1.6)	0.88 (-2.5, 5.)	-0.21 (-1.8, 1.5)	0.448976
Standard-term, extended-term	-0.049 (-1.3, 1.2)	-1.4 (-5.6, 2.3)	-0.14 (-1.3, 0.91)	0.466592
Target vessel revascularization				
Midterm, standard-term	-0.52 (-1.7, 0.73)	-0.17 (-2.7, 2.4)	-0.46 (-1.5, 0.63)	0.79308
Midterm, extended-term	-0.056 (-2.2, 2.0)	-0.40 (-2.2, 1.6)	-0.27 (-1.6, 1.1)	0.80382
Standard-term, extended-term	0.12 (-1.3, 1.6)	0.45 (-2.0, 2.8)	0.19 (-0.99, 1.4)	0.80168
Definite or probable stent thrombosis				
Short-term, standard-term	0.43 (-2.3, 3.8)	0.28 (-4.6, 4.1)	0.40 (-1.9, 2.7)	0.944304
Short-term, extended-term	0.46 (-2.9, 3.8)	0.68 (-2.8, 5.6)	0.44 (-1.6, 3.2)	0.937040
Standard-term, extended-term	0.18 (-2.1, 3.5)	0.031 (-4.9, 4.3)	0.044 (-1.8, 2.5)	0.938640
Major bleeding				
Short-term, standard-term	-0.16 (-1.5, 0.83)	0.57 (-1.0, 2.1)	0.052 (-0.87, 0.86)	0.32981
Short-term, extended-term	1.1 (-0.15, 2.4)	0.38 (-1.2, 1.7)	0.79 (-0.14, 1.7)	0.33804
Standard-term, extended-term	0.53 (-0.38, 1.5)	1.3 (-0.30, 3.1)	0.73 (-0.021, 1.5)	0.33471

Table S8. Estimate results according to the network meta-analysis on other endpoint

Primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy			
Aspirin			
1.12 (0.66, 1.84)	P2Y12 inhibitor		
0.91 (0.61, 1.36)	0.82 (0.6, 1.14)	DAPT	
All-cause mortality			
Short-term DAPT			
0.91 (0.24, 3.5)	Midterm DAPT		
1 (0.38, 2.84)	1.1 (0.42, 3.01)	Standard-term DAPT	
0.72 (0.26, 1.93)	0.79 (0.27, 2.21)	0.72 (0.34, 1.36)	Extended-term DAPT
Cardiac mortality			
Short-term DAPT			
0.71 (0.19, 2.52)	Midterm DAPT		
0.83 (0.36, 1.85)	1.17 (0.41, 3.37)	Standard-term DAPT	
0.92 (0.42, 2.21)	1.32 (0.42, 4.3)	1.11 (0.59, 2.35)	Extended-term DAPT
Myocardial infarction			
Short-term DAPT			
0.62 (0.19, 1.69)	Midterm DAPT		
0.68 (0.27, 1.58)	1.09 (0.57, 2.3)	Standard-term DAPT	
0.84 (0.34, 1.94)	1.35 (0.59, 3.44)	1.24 (0.65, 2.39)	Extended-term DAPT
Stroke			
Short-term DAPT			
3.05 (0.3, 33.86)	Midterm DAPT		
1.07 (0.16, 5.57)	0.35 (0.06, 1.47)	Standard-term DAPT	
1.23 (0.22, 5.92)	0.41 (0.05, 2.45)	1.15 (0.4, 3.74)	Extended-term DAPT
Target vessel revascularization			
Short-term DAPT			
0.89 (0.21, 4.2)	Midterm DAPT		
1.41 (0.49, 4.23)	1.59 (0.54, 4.35)	Standard-term DAPT	
1.15 (0.24, 5.75)	1.29 (0.33, 4.69)	0.81 (0.25, 2.64)	Extended-term DAPT
Definite or probable stent thrombosis			
Short-term DAPT			

0.13 (0, 3.08)	Midterm DAPT		
0.66 (0.06, 6.43)	5.2 (0.51, 119.6)	Standard-term DAPT	
0.64 (0.04, 5.11)	4.9 (0.17, 174.8)	0.96 (0.08, 6.08)	Extended-term DAPT
Major bleeding			
Short-term DAPT			
1.27 (0.3, 5.77)	Midterm DAPT		
0.95 (0.43, 2.37)	0.75 (0.22, 2.57)	Standard-term DAPT	
0.46 (0.19, 1.15)	0.36 (0.08, 1.5)	0.48 (0.21, 1.02)	Extended-term DAPT

Table S9. Bayesian ranking results of network meta-analysis

Treatment	The rank of possibility (%)			
	1	2	3	4
Primary endpoint				
Short-term DAPT	**78.18**	14.83	6.49	0.50
Midterm DAPT	12.38	21.02	62.84	3.76
Standard-term DAPT	9.18	63.55	26.84	0.43
Extended-term DAPT	0.26	0.60	3.82	**95.32**
Primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy				
Aspirin	32.28	36.76	30.96	
P2Y12 inhibitor	**64.36**	27.67	7.97	
DAPT	3.36	35.57	**61.07**	
All-cause mortality				
Short-term DAPT	**37.59**	25.87	21.38	15.16
Midterm DAPT	30.45	20.40	22.85	26.30
Standard-term DAPT	29.00	42.84	23.06	5.10
Extended-term DAPT	2.97	10.89	32.71	**53.43**
Cardiac mortality				
Short-term DAPT	**42.98**	25.33	18.33	13.36
Midterm DAPT	19.24	13.02	15.17	**52.57**
Standard-term DAPT	11.86	27.17	40.44	20.53
Extended-term DAPT	25.93	34.48	26.05	13.54
Myocardial infarction				
Short-term DAPT	**64.05**	20.33	8.72	6.90
Midterm DAPT	8.14	12.92	24.67	**54.27**
Standard-term DAPT	4.69	16.07	49.40	29.84
Extended-term DAPT	23.11	50.68	17.21	9.00
Stroke				
Short-term DAPT	12.19	23.49	18.17	**46.15**
Midterm DAPT	**76.61**	12.50	6.72	4.17
Standard-term DAPT	1.86	27.15	37.89	33.10
Extended-term DAPT	9.34	36.86	37.22	16.58
Target vessel revascularization				
Short-term DAPT	16.15	22.29	28.48	33.08
Midterm DAPT	10.66	16.07	29.75	**43.52**
Standard-term DAPT	**44.92**	38.44	14.32	2.32
Extended-term DAPT	28.27	23.20	27.45	21.08
Definite or probable stent thrombosis				
Short-term DAPT	**52.67**	25.32	17.35	4.66
Midterm DAPT	3.55	5.10	10.17	**81.18**
Standard-term DAPT	22.56	35.57	39.29	2.58
Extended-term DAPT	21.23	34.01	33.18	11.58

Major bleeding				
Short-term DAPT	27.42	36.36	33.15	3.07
Midterm DAPT	**59.08**	15.76	18.98	6.18
Standard-term DAPT	13.04	46.09	39.42	1.45
Extended-term DAPT	0.46	1.77	8.45	**89.32**

Table S10. Estimate results of sensitivity analyses

a) Type of monotherapy after short-term DAPT

Primary endpoint				
Short-term DAPT [P2Y12 inhibitor]				
0.92 (0.4, 2.18)	Short-term DAPT [Asprin]			
0.68 (0.32, 1.45)	0.73 (0.34, 1.59)	Midterm DAPT		
0.83 (0.47, 1.49)	0.9 (0.48, 1.65)	1.22 (0.76, 1.96)	Standard-term DAPT	
0.54 (0.23, 1.18)	0.58 (0.24, 1.3)	0.8 (0.43, 1.4)	0.65 (0.36, 1.11)	Extended-term DAPT
All-cause mortality				
Short-term DAPT [P2Y12 inhibitor]				
0.59 (0.07, 5.36)	Short-term DAPT [Asprin]			
0.6 (0.09, 3.83)	1.02 (0.15, 6.43)	Midterm DAPT		
0.66 (0.14, 3.12)	1.11 (0.24, 5.19)	1.09 (0.38, 3.33)	Standard-term DAPT	
0.48 (0.08, 2.68)	0.82 (0.13, 4.51)	0.8 (0.25, 2.55)	0.74 (0.29, 1.64)	Extended-term DAPT
Cardiac mortality				
Short-term DAPT [P2Y12 inhibitor]				
0.62 (0.09, 3.53)	Short-term DAPT [Asprin]			
0.54 (0.09, 2.77)	0.88 (0.19, 4.13)	Midterm DAPT		
0.62 (0.14, 2.41)	1 (0.33, 3.01)	1.14 (0.38, 3.43)	Standard-term DAPT	
0.77 (0.24, 2.48)	1.24 (0.34, 5.28)	1.42 (0.44, 5.17)	1.24 (0.58, 3.06)	Extended-term DAPT
Myocardial infarction				
Short-term DAPT [P2Y12 inhibitor]				
0.69 (0.11, 6.16)	Short-term DAPT [Asprin]			
0.52 (0.1, 2.53)	0.75 (0.13, 2.78)	Midterm DAPT		
0.56 (0.13, 2.63)	0.81 (0.19, 2.59)	1.09 (0.54, 2.5)	Standard-term DAPT	

0.75 (0.21, 2.71)	1.08 (0.19, 4.19)	1.44 (0.55, 4.02)	1.33 (0.58, 2.85)	Extended-term DAPT
Stroke				
Short-term DAPT [P2Y12 inhibitor]				
3.51 (0.05, 398.9)	Short-term DAPT [Asprin]			
2.41 (0.15, 46.73)	0.7 (0.01, 28.78)	Midterm DAPT		
1.36 (0.08, 18.44)	0.39 (0.01, 10.17)	0.57 (0.1, 2.15)	Standard-term DAPT	
1.61 (0.17, 16.42)	0.48 (0.01, 17.93)	0.68 (0.11, 3.56)	1.19 (0.32, 5.75)	Extended-term DAPT
Definite or probable stent thrombosis				
Short-term DAPT [P2Y12 inhibitor]				
0.24 (0, 27.58)	Short-term DAPT [Asprin]			
0.06 (0, 3.22)	0.25 (0, 14.95)	Midterm DAPT		
0.34 (0.01, 9.01)	1.38 (0.04, 42.57)	5.5 (0.48, 141.3)	Standard-term DAPT	
0.4 (0.01, 5.2)	1.65 (0.02, 87.32)	6.52 (0.18, 322)	1.21 (0.08, 10.9)	Extended-term DAPT
Major bleeding				
Short-term DAPT [P2Y12 inhibitor]				
0.24 (0, 27.58)	Short-term DAPT [Asprin]			
0.06 (0, 3.22)	0.25 (0, 14.95)	Midterm DAPT		
0.34 (0.01, 9.01)	1.38 (0.04, 42.57)	5.5 (0.48, 141.3)	Standard-term DAPT	
0.4 (0.01, 5.2)	1.65 (0.02, 87.32)	6.52 (0.18, 322)	1.21 (0.08, 10.9)	Extended-term DAPT

b) Exclusion of trials with high risks of bias

Primary endpoint				
Short-term DAPT [P2Y12 inhibitor]				
0.92 (0.17, 5.19)	Short-term DAPT [Asprin]			

0.64 (0.13, 3.12)	0.69 (0.19, 2.55)	Midterm DAPT		
0.77 (0.2, 3.01)	0.84 (0.29, 2.33)	1.21 (0.54, 2.68)	Standard-term DAPT	
0.67 (0.12, 3.75)	0.73 (0.17, 3.15)	1.05 (0.42, 2.67)	0.87 (0.31, 2.49)	Extended-term DAPT
All-cause mortality				
Short-term DAPT [P2Y12 inhibitor]				
0.6 (0.19, 1.87)	Short-term DAPT [Asprin]			
0.91 (0.27, 3.09)	1.51 (0.46, 5.22)	Midterm DAPT		
0.67 (0.3, 1.48)	1.1 (0.49, 2.49)	0.74 (0.29, 1.77)	Standard-term DAPT	
0.64 (0.25, 1.73)	1.07 (0.42, 2.9)	0.71 (0.29, 1.71)	0.96 (0.58, 1.7)	Extended-term DAPT
Cardiac mortality				
Short-term DAPT [P2Y12 inhibitor]				
0.61 (0.09, 3.44)	Short-term DAPT [Asprin]			
0.69 (0.11, 3.83)	1.14 (0.22, 6.21)	Midterm DAPT		
0.6 (0.13, 2.32)	0.99 (0.33, 3.04)	0.87 (0.24, 3)	Standard-term DAPT	
0.77 (0.23, 2.5)	1.27 (0.34, 5.65)	1.13 (0.3, 4.45)	1.29 (0.61, 3.29)	Extended-term DAPT
Myocardial infarction				
Short-term DAPT [P2Y12 inhibitor]				
0.79 (0.08, 12.35)	Short-term DAPT [Asprin]			
0.46 (0.06, 3.73)	0.58 (0.07, 3.16)	Midterm DAPT		
0.61 (0.09, 4.65)	0.78 (0.14, 3.16)	1.34 (0.48, 4.41)	Standard-term DAPT	
0.74 (0.15, 3.72)	0.94 (0.11, 5.08)	1.62 (0.43, 6.2)	1.22 (0.37, 3.41)	Extended-term DAPT
Stroke				
Short-term DAPT [P2Y12 inhibitor]				
3.07 (0.15, 117.5)	Short-term DAPT			

	[Asprin]			
1.58 (0.27, 9.55)	0.52 (0.02, 8.2)	Midterm DAPT		
1.38 (0.29, 6.71)	0.47 (0.02, 5.84)	0.88 (0.29, 2.66)	Standard-term DAPT	
1.62 (0.45, 6.3)	0.54 (0.02, 7.92)	1.04 (0.32, 3.48)	1.17 (0.51, 2.85)	Extended-term DAPT
Definite or probable stent thrombosis				
Short-term DAPT [P2Y12 inhibitor]				
0.24 (0, 27.58)	Short-term DAPT [Asprin]			
0.06 (0, 3.22)	0.25 (0, 14.95)	Midterm DAPT		
0.34 (0.01, 9.01)	1.38 (0.04, 42.57)	5.5 (0.48, 141.3)	Standard-term DAPT	
0.4 (0.01, 5.2)	1.65 (0.02, 87.32)	6.52 (0.18, 322)	1.21 (0.08, 10.9)	Extended-term DAPT

c) 1 to 3-month DAPT followed monotherapy

Primary endpoint					
1-month DAPT [Clopidogrel]					
0.9 (0.19, 4.23)	1-month DAPT [Ticagrelor]				
0.73 (0.2, 2.68)	0.81 (0.25, 2.69)	3-month DAPT			
0.57 (0.16, 2)	0.63 (0.2, 1.99)	0.78 (0.36, 1.67)	Midterm DAPT		
0.69 (0.22, 2.2)	0.77 (0.28, 2.17)	0.95 (0.53, 1.7)	1.22 (0.74, 2.03)	Standard-term DAPT	
0.45 (0.11, 1.58)	0.5 (0.14, 1.58)	0.62 (0.25, 1.36)	0.79 (0.4, 1.45)	0.65 (0.33, 1.14)	Extended-term DAPT

d) Exclusion of GLOBAL LEADERS and TWILIGHT studies

Primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy		
Aspirin		
1.02 (0.53, 1.98)	P2Y12 inhibitor	
0.91 (0.6, 1.37)	0.89 (0.54, 1.47)	DAPT

Table S11. Bayesian ranking results of primary endpoint after sensitivity analyses

a) Type of monotherapy after short-term DAPT

Treatment	The rank of possibility (%)				
	1	2	3	4	5
Primary endpoint					
Short-term DAPT [P2Y12 inhibitor]	**53.54**	35.74	3.99	5.78	0.95
Short-term DAPT [Asprin]	25.87	29.76	8.84	33.16	2.37
Midterm DAPT	11.23	18.11	15.86	50.15	4.65
Standard-term DAPT	6.35	11.00	54.84	9.86	17.95
Extended-term DAPT	3.01	5.39	16.47	1.04	**74.09**
All-cause mortality					
Short-term DAPT [P2Y12 inhibitor]	**57.12**	18.53	14.66	6.62	3.07
Short-term DAPT [Asprin]	17.35	19.71	22.19	32.10	8.65
Midterm DAPT	9.18	15.48	19.59	38.90	16.85
Standard-term DAPT	7.99	16.94	22.95	18.81	33.31
Extended-term DAPT	8.35	29.34	20.61	3.57	**38.13**
Cardiac mortality					
Short-term DAPT [P2Y12 inhibitor]	**53.47**	17.17	11.15	4.70	13.51
Short-term DAPT [Asprin]	17.99	15.86	12.46	14.24	**39.45**
Midterm DAPT	10.14	16.97	16.23	31.18	25.48
Standard-term DAPT	8.98	20.59	19.55	35.72	15.16
Extended-term DAPT	9.41	29.42	40.62	14.15	6.40
Myocardial infarction					
Short-term DAPT [P2Y12 inhibitor]	**57.97**	25.46	3.84	2.12	10.61
Short-term DAPT [Asprin]	19.15	19.16	8.98	9.13	**43.58**
Midterm DAPT	8.15	19.05	18.32	26.48	28.00
Standard-term DAPT	6.22	13.20	26.09	42.44	12.05
Extended-term	8.51	23.14	42.76	19.83	5.76

DAPT					
Stroke					
Short-term DAPT [P2Y12 inhibitor]	9.84	52.05	28.24	2.16	7.71
Short-term DAPT [Asprin]	12.23	12.41	37.53	13.67	24.16
Midterm DAPT	12.32	7.64	17.15	30.84	**32.05**
Standard-term DAPT	16.39	9.99	11.36	33.81	28.45
Extended-term DAPT	**49.22**	17.92	5.71	19.52	7.63
Definite or probable stent thrombosis					
Short-term DAPT [P2Y12 inhibitor]	**59.78**	18.48	1.83	9.08	10.83
Short-term DAPT [Asprin]	18.55	15.37	3.59	23.98	**38.51**
Midterm DAPT	10.59	15.70	6.60	42.72	24.39
Standard-term DAPT	7.79	30.62	19.53	22.68	19.38
Extended-term DAPT	3.30	19.82	68.45	1.54	6.89

b) Exclusion of trials with high risks of bias

Primary endpoint					
Short-term DAPT [P2Y12 inhibitor]	**44.82**	33.14	4.97	5.17	11.90
Short-term DAPT [Asprin]	20.24	26.66	12.01	25.19	15.90
mMidterm DAPT	11.39	15.00	18.22	39.21	16.18
Standard-term DAPT	9.06	11.51	32.64	22.01	24.78
Extended-term DAPT	14.49	13.69	32.15	8.43	**31.24**
All-cause mortality					
Short-term DAPT [P2Y12 inhibitor]	**49.22**	8.26	37.39	1.44	3.69
Short-term	26.93	15.31	28.63	14.13	15.00

DAPT [Asprin]					
Midterm DAPT	10.50	15.96	12.69	35.52	25.33
Standard-term DAPT	7.11	16.59	10.93	36.48	**28.89**
Extended-term DAPT	6.25	43.86	10.37	12.42	27.10
Cardiac mortality					
Short-term DAPT [P2Y12 inhibitor]	**49.01**	14.49	21.83	2.90	11.77
Short-term DAPT [Asprin]	20.59	15.12	17.49	10.84	**35.96**
Midterm DAPT	11.24	16.39	17.68	25.89	28.80
Standard-term DAPT	9.06	19.78	15.87	39.11	16.18
Extended-term DAPT	10.11	34.22	27.13	21.24	7.30
Myocardial infarction					
Short-term DAPT [P2Y12 inhibitor]	**49.10**	32.18	3.76	4.67	10.29
Short-term DAPT [Asprin]	19.87	19.46	7.88	16.61	**36.18**
Midterm DAPT	10.14	16.98	14.00	30.67	28.21
Standard-term DAPT	9.38	14.38	22.07	36.58	17.59
Extended-term DAPT	11.51	16.99	52.29	11.47	7.74
Stroke					
Short-term DAPT [P2Y12 inhibitor]	7.57	58.83	16.43	4.44	12.73
Short-term DAPT	12.38	9.25	27.61	19.41	**31.35**

[Asprin]					
Midterm DAPT	11.98	6.80	19.28	31.30	30.64
Standard-term DAPT	18.42	9.10	20.83	30.75	20.90
Extended-term DAPT	**49.64**	16.01	15.86	14.10	4.39
Definite or probable stent thrombosis					
Short-term DAPT [P2Y12 inhibitor]	**59.78**	18.48	1.83	9.08	10.83
Short-term DAPT [Asprin]	18.55	15.37	3.59	23.98	**38.51**
Midterm DAPT	10.59	15.70	6.60	42.72	24.39
Standard-term DAPT	7.79	30.62	19.53	22.68	19.38
Extended-term DAPT	3.30	19.82	68.45	1.54	6.89

c) 1 to 3-month DAPT followed monotherapy

Primary endpoint						
1-month DAPT [Clopidogrel]	**50.02**	35.10	10.49	1.87	2.00	0.52
1-month DAPT [Ticagrelor]	21.05	32.04	24.66	6.13	14.48	1.64
3-month DAPT	8.47	11.37	27.23	11.09	38.48	3.35
Midterm DAPT	7.63	8.51	20.25	19.86	36.80	6.95
Standard-term DAPT	6.37	6.80	12.02	46.52	7.46	20.83
Extended-term DAPT	6.45	6.18	5.35	14.53	0.77	**66.72**

d) Exclusion of GLOBAL LEADERS and TWILIGHT studies

Primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy				
Aspirin	41.68	32.06	26.26	
P2Y12 inhibitor	**48.03**	24.38	27.59	
DAPT	10.29	43.57	**46.14**	



Figure S1. The detailed risk of bias assessments

A. History for primary endpoint



B. Brooks-Gelman-Rubin diagnostic for primary endpoint



C. History for all-cause mortality



D. Brooks-Gelman-Rubin diagnostic for all-cause mortality



E. History for cardiac mortality



F. Brooks-Gelman-Rubin diagnostic for cardiac mortality



G. History for myocardial infarction



H. Brooks-Gelman-Rubin diagnostic for myocardial infarction



I. History for stroke



J. Brooks-Gelman-Rubin diagnostic for stroke



K. History for target vessel revascularization



L. Brooks-Gelman-Rubin diagnostic for target vessel revascularization



M. History for definite or probable stent thrombosis



N. Brooks-Gelman-Rubin diagnostic for definite or probable stent thrombosis



O. History for major bleeding



P. Brooks-Gelman-Rubin diagnostic for major bleeding

Figure S2. The convergence of the chains established by inspection of the history featured and the Brooks-Gelman-Rubin diagnosis for primary endpoint (A and B), all-cause mortality (C and D), cardiac mortality (E and F), myocardial infarction (G and H), stroke (I and J), target vessel revascularization (K and L), definite or probable stent thrombosis (M and N), major bleeding (O and P)



A. Network evidence plot for primary endpoint



B. Network evidence plot for all-cause mortality



C. Network evidence plot for cardiac mortality



D. Network evidence plot for MI



E. Network evidence plot for stroke



F. Network evidence plot for TVR



G. Network evidence plot for stent thrombosis



H. Network evidence plot for major bleeding

Figure S3. The network plot of secondary outcomes

A. Ranking curve for primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy



B. Cumulative ranking curve for primary endpoint with short-term DAPT followed by P2Y12 inhibitor or aspirin monotherapy



C. Ranking curve for all-cause mortality



D. Cumulative ranking curve for all-cause mortality



E. Ranking curve for cardiac mortality



F. Cumulative ranking curve for cardiac mortality



G. Ranking curve for myocardial infarction



H. Cumulative ranking curve for myocardial infarction



I. Ranking curve for stroke



J. Cumulative ranking curve for stroke



K. Ranking curve for target vessel revascularization



L. Cumulative ranking curve for target vessel revascularization



M. Ranking curve for definite or probable stent thrombosis



N. Cumulative ranking curve for definite or probable stent thrombosis



O. Ranking curve for major bleeding



P. Cumulative ranking curve for major bleeding



Figure S4. Ranking and cumulative ranking curve for secondary outcomes